Copenhagen-based Bactolife raises €30M to bring exclusive ‘Binding Proteins’ to market to improve gut health
Summary
The round was led by ATHOS, with participation from the Bill & Melinda Gates Foundation and existing investor Novo Holdings. These proteins have been specifically developed to enhance the gut microbiome of both humans and animals, with the ultimate goal of reducing gastrointestinal infections and combating the problem of antimicrobial resistance. Sebastian Søderberg, CEO of Bactolife says, “We are very pleased and humbled by the continued confidence that investors have shown us, especially in times of geopolitical uncertainty and market turmoil. The funding allows us to increase our investments in our project pipeline, technology platform, organisation and upscaling capabilities. Further, it will enable Bactolife to accelerate our partnering efforts with world-leading companies and commercialise our first product concepts for humans and animals.” ATHOS Investment Manager Julian Zachmann says that infectious diseases and the rising problem of antimicrobial resistance pose significant threats to global health and development.